Researchers at Karolinska Institutet in Sweden have managed to sequence the giant genome of a salamander, the Iberian ribbed newt, which is a full six times greater than the human genome.
Amongst the early findings is a family of genes that can provide clues to the unique ability of salamanders to rebuild complex tissue, even body parts. The study is published in Nature Communications.
This is the first time that an entire newt genome has been sequenced, an achievement that can give rise to new discoveries on the amphibian’s ability to recreate brain neurons as well as entire body parts. Amongst the first findings are a multitude of copies of a certain microRNA group, which in mammals is mainly found in embryonic stem cells, but also in tumour cells.
“It will be exciting to figure out how regeneration in the adult organism re-activates embryonic genes,” says study leader Professor András Simon at Karolinska Institutet’s Department of Cell and Molecular Biology. “What’s needed now are functional studies of these microRNA molecules to understand their function in regeneration. The link to cancer cells is also very interesting, especially bearing in mind newts’ marked resistance to tumour formation.”
Even though the abundance of stem cell microRNA genes is quite surprising, it alone cannot explain how salamanders regenerate so well. Professor Simon predicts that the explanation lies in a combination of genes unique to salamanders and how other more common genes orchestrate and control the actual regeneration process.
One of the reasons why salamander genomes have not been sequenced before is its sheer size – six times bigger than the human genome in the case of the Iberian newt, which has posed an enormous technical and methodological challenge.
“It’s only now that the technology is available to handle such a large genome,” says Professor Simon. “The sequencing per se doesn’t take that long – it’s recreating the genome from the sequences that’s so time consuming.”
“We all realised how challenging it was going to be,” recounts first author Ahmed Elewa, postdoctoral fellow at the same department. “But the very fact that it was such a challenge made it all the more exciting.”
The group at Karolinska Institutet is now engaging with other researchers to discover what can be learned from the newt genome and test new hypotheses through systematic comparisons with mammals.
“We showed ten years ago that salamanders can recreate all the cells that die in Parkinson’s disease in the space of four weeks,” says Professor Simon. “We can now delve deeply into the molecular processes underlying this ability. Although we’re doing basic research, our findings can hopefully lead to the development of new regenerative strategies for humans.”
The Latest on: Regenerative medicine
Regenerative medicine firm CollPlant launches Israel R&D center
on May 23, 2019 at 9:30 am
As you can imagine, more people are reading The Jerusalem Post than ever before. Nevertheless, traditional business models are no longer sustainable and high-quality publications, like ours, are being ... […]
New Progress in Stem-Cell-Free Regenerative Medicine
on May 23, 2019 at 7:00 am
Regenerative medicine and stem cells are often uttered within the same breath, for good reason. Yet stem cells are hard to procure, manufacture, and grow. And unless they’re made from the patient’s ... […]
Visiongain Report Analyses Leading Players Within the Translational Regenerative Medicine Manufacturers Market
on May 23, 2019 at 2:00 am
LONDON, May 23, 2019 /PRNewswire/ -- In 2018, the global translational regenerative medicine is estimated at $28bn. The global translational regenerative medicine market is highly competitive and ... […]
2019 Regenerative Medicine Market Analysis Report with Innovative Business Strategies, Key Players, Drivers and Opportunities Forecast 2024
on May 22, 2019 at 11:27 am
May 22, 2019 (Reporthive Research via COMTEX) -- Regenerative Medicine Market research report covers market share, size, CAGR,industry analysis, market strategy, statistical analysis, sales, revenue, ... […]
Regenerative medicine firm CollPlant launches Israel R&D centre
on May 22, 2019 at 5:32 am
TEL AVIV, May 22 (Reuters) - CollPlant, which makes products for tissue repair and organ manufacturing from its recombinant human collagen, has launched a new research and development centre in Israel ... […]
Enso Discoveries and Dr. Corey Orava, DVM, Announce a First of its Kind, Patent Pending, Regenerative Medicine Therapy for Veterinarians
on May 16, 2019 at 6:05 pm
Under the guidance of leading Regenerative Medicine expert and Chief Scientific Officer Dr. Corey Orava, DVM, Enso Discoveries has developed and university-validated an effective, multi-species ... […]
NextCell Pharma invited speaker at the World Advanced Therapies & Regenerative Medicine Congress
on May 15, 2019 at 1:14 am
NextCell Pharma AB ("NextCell") and Cellaviva have been invited to attend and speak at the 14th annual World Advanced Therapies & Regenerative Medicine Congress, which is held at the Business Design ... […]
U of T's Medicine by Design invests $1.2 million to advance regenerative medicine research and translation
on May 14, 2019 at 1:24 pm
Leo Chou, an assistant professor at U of T’s Institute of Biomaterials & Biomedical Engineering and an investigator at Medicine by Design, is leading one of four projects selected for the 2019 New ... […]
“Global translational regenerative medicine market set to grow to $95bn by 2024”, says new Visiongain report
on May 14, 2019 at 1:51 am
Visiongain has published a new Pharma Report Top 25 Translational Regenerative Medicine Manufacturers 2019: Medtronic, Acelity, Integra Lifesciences, NuVasive, Orthofix International, Anika ... […]
Regulatory Intelligence: Update on Regenerative Medicine Advanced Therapies Designations
on May 13, 2019 at 9:17 am
Section 3033 of the 21 st Century Cures Act, titled “Accelerated Approval for Regenerative Advanced Therapies,” created a special designation for Regenerative Medicine Advanced Therapies (RMAT). A ... […]
via Google News and Bing News